Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: The opportunities of diabetes in Asia

“The Asia-Pacific region presents lucrative opportunities for multinational pharmaceutical firms that treat diabetes,” says BMI Research in Singapore in a new report on healthcare in Asia. Fuelled by rapid urbanisation, nutrition transition and increasingly sedentary lifestyles, the epidemic has grown in parallel with the worldwide rise in obesity. Asia’s large population and rapid economic development have made it an epicentre of the epidemic, with India and China the key hotspots in the region, it explains.

The World Health Organisation (WHO) reckons that 80% of diabetes deaths occur in low- and middle-income countries, and forecasts that these deaths will double between 2016 and 2030. The epidemic of diabetes, as well as the burden of related non-communicable diseases, is challenging public health and hospital systems around the world – particularly in the Asia-Pacific region. Though the prevalence of obesity in Asia is relatively low compared with that across Western populations, BMI argues that Asia Pacific’s vast population and rapid economic development presents significant opportunities for companies in diabetes therapeutic field.

The size of the problem is significant. Patients with diabetes in Asia now account for more than 60% of the global diabetic population, with the majority residing in the largest and most populous countries; India and China.

 “We note that India and China are by far the two largest markets in the region for diabetes medicines,” writes BMI. According to International Diabetes Federation, there were 69.1 million cases of diabetes in India in 2015 and 109 million cases of diabetes in China. Last year, India’s population lost 9.2 million disability-adjusted life years to diabetes, China lost 8.2 million years and Indonesia lost 2.9 million years. “The significant increase in the prevalence of diabetes in India and China has occurred over a short period of time, largely driven by sedentary lifestyles and unhealthy diets,” it adds.

Due to elevated behavioural risks causing a strain on the region’s healthcare systems, governments have begun to introduce initiatives aimed at reversing this trend. Moreover, given the high financial burden of treating diabetes, there will be greater emphasis placed on preventative care. In India, BMI cites a national programme for control of diabetes has been rolled out across the country, to improve diabetes awareness levels at a national level. The government has also imposed a hefty tax of 28% on diabetes-inducing food substances under the Goods and Services Tax regime in an attempt to dissuade consumption of unhealthy food. And in China, World Diabetes Day and several similarly themed publicity events have been used to spread information on diabetes prevention and to raise public health literacy. Public health lifestyle campaigns have been pushed forward to advocate rational diet and adequate exercise, and to discourage smoking and the consumption of alcohol.

Posted on: 14/06/2017 UTC+08:00


News

Beijing-based healthcare service platform Miaoshou Doctor has completed a ¥1.5 billion (US$232 million) Series F round of financing.
Chinese digital technology company, Xisoft Technology, which focuses on hospital operation management, has raised ¥100 million ($15.65 million) in Series A+ financing.
Hearing health company Olive Union has closed a $7M Series B round led by Beyond Next Ventures, Bonds Investment Groups and Japan Policy Finance Corporation.
Long Hill Capital, a venture capital firm in China, has closed on more than $300 million for its third fund on 15 March.
Eluminex Biosciences, an ophthalmic biotechnology company has completed a $50 million Series A financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital.
TVM Capital Healthcare, a global private equity and growth capital firm focused on emerging markets, has announced two team additions today.
In partnership with VeChain and DNV GL, Renji Hospital, a hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has launched the world's first blockchain-enabled intelligent tumour treatment centre.
Hong Kong-based BuyHive, a new global sourcing start-up that connects buyers with trusted verified overseas suppliers, has launched a PPE programme to help US companies optimise their post-Covid supply chains.



Analysis

L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.


Podcasts

HealthInvestor Asia twitter feed










A Rolex Yacht-Master I Ladies Replica watch is basically a person watch that's crafted inside an identical fashion with a well-known maker¡¯s real piece. Purchasing Replica Watches seems as an excellent idea. Anyway,ON perfectcloneshop.com replica Rolex Yacht-Master Ladies watches are affordable, look almost the identical while using real ones and could easily acquired.